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Background: Cystic fibrosis (CF) is a life-threatening chronic inflammatory disease in children 
due to respiratory complications. Saliva could serve as reservoir of bacterial colonization and 
potentially reflect systemic inflammation. This study investigated whether salivary triggering 
receptor expressed on myeloid cells 1 (TREM-1), peptidoglycan recognition protein 1 
(PGLYRP1), interleukin (IL)-1β and calprotectin are associated with CF or reflect concomitant 
gingival inflammation. 
Methods: Ten CF (age:3-12yrs) and ten systemically healthy age-and-gender-matched 
children (C) were enrolled in the study. Individuals with CF underwent routine laboratory 
determinations. Probing pocket depth (PPD), gingival index (GI), plaque index (PI) and 
bleeding on probing (BOP) were recorded on fully erupted teeth
 
and saliva samples collected. 
Salivary TREM-1, PGLYRP1, IL-1β and calprotectin were analysed by ELISA. 
Results: Children with CF had significantly higher BOP scores (P=0.001) and calprotectin 
levels (P=0.017) compared to the C group. TREM-1, PGLYRP1 and IL-1β could not 
distinguish between CF and SH but showed positive correlation with GI, PI and BOP in both 
groups. Calprotectin levels positively correlated with procalcitonin (P=0.014), thrombocyte 
counts (P=0.001), mean platelet volume (P=0.030) and with PGLYRP1 (P=0.019) and IL-1β 
(P=0.013) in CF children. Receiver operating characteristic curve analysis for calprotectin 
(CFvsC) showed an area under the curve of 0.79 (95% CI 0.58-0.99, P=0.034). 
Conclusions: CF children presented with higher gingival inflammation scores and salivary 
calprotectin levels, that correlated with systemic inflammatory markers. Salivary calprotectin 
levels were not associated with periodontal parameters. Hence, preliminary data demonstrate 
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1. Introduction 
 Cystic fibrosis (CF), a life-threatening chronic inflammatory disease, is linked to a 
mutation in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) 
protein1. In CF children, the most significant reason of morbidity or mortality is due to 
persistent bacterial colonization of the lung and nasal mucosa2. However, the mechanisms that 
allow persistent colonization of pathogens are not well understood. The oral cavity harbours 
more than 700 species and has therefore been suggested as one of the potential reservoirs1. The 
association between CF and caries risk has been established in young children, but relatively 
less information exists on its association with periodontal inflammation3-6. Although children 
with CF are reported to have a higher prevalence of calculus due to deregulated calcium and 
phosphate levels in their saliva3, it is not conclusive if other salivary factors are associated with 
and/or reflect CF. There is an increasing evidence that expression of triggering receptor 
expressed on myeloid cells 1 (TREM-1), along with its putative ligand peptidoglycan recognition 
protein 1 (PGLYRP1), is significantly increased in saliva in the presence of chronic inflammatory 
diseases including periodontal disease7,8. Activation of TREM-1 triggers amplification of 
proinflammatory cytokine production such as tumor necrosis factor (TNF)- and interleukin 
(IL)-1β7, which in return can help to eliminate pathogens. Interestingly, TREM-1 has been 
shown to be down-regulated in monocytic cells from patients with CF or was not detectable at 
all in their serum9. However, a small pilot study from 201710 showed significantly elevated 
TREM-1 levels in plasma of CF patients. PGLYRP1, recently identified as a ligand for TREM-1, is 
an antimicrobial peptide expressed in neutrophils11. Earlier work indicates that PGLYRP1 is 
involved in exacerbation of airway inflammation and the development of allergic asthma12, yet 
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of CF antigen or namely calprotectin in their plasma, sputum and, to a lesser extent in their 
saliva13,14. Nonetheless, the regulation of TREM-1, PGYLRP1 and calprotectin in saliva of CF 
patients in the presence or absence of gingival inflammation has not been studied so far. 
Therefore, in the present study we investigated whether salivary TREM-1, PGYLRP1 and 
calprotectin are associated with CF or are rather a result of or reflect concomitant gingival 
inflammation. 
 
2. Materials and Methods 
2.1. Study Population 
Ten children with CF aged 3 to 12 years old followed by the Department of Pediatric 
Gastroenterology, Faculty of Medicine, Adnan Menderes University, Aydın, Turkey from May 
2016 until April 2018 were recruited for this study. CF patients having no other systemic 
disease, who did not need a lung transplantation and were clinically and symptomatically stable, 
free of acute respiratory infections for at least 4 weeks were included.  Their routine clinical 
tests included the following measurements: C-reactive protein (CRP), haemoglobin, 
haematocrit, mean cell volume (MCV), erythrocyte, mean corpuscular haemoglobin (MCH), 
mean corpuscular haemoglobin concentration (MCHC), red cell distribution width (RDW), 
leukocyte, neutrophil, lymphocyte, monocyte, eosinophil, basophil, thrombocyte, procalcitonin 
(PCT), mean platelet volume (MPV). Patients were excluded who had been administered 
probiotics or anti-inflammatory drugs or were on the waiting list for lung transplantation or 
had pulmonary exacerbation and used oral or intravenous antibiotics within the past four 
months15. Ten systemically healthy age and sex matched children who visited the Faculty of 
Dentistry, Adnan Menderes University, Aydın, Turkey for dental check-ups were enrolled as a 
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inflammatory drugs within the past four months, having caries or less than ten fully-erupted 
teeth were criteria for exclusion.  The Ethics Committee of Ege University approved the study 
protocols following the ethical principles stated in the World Medical Association Declaration of 
Helsinki (Protocol Number: 18-9.1/30). The design and the aim of this study were explained in 
detail prior to the clinical periodontal evaluation and informed consent was obtained from all 
participants (parents (in writing) and children (orally)). 
 
2.2. Clinical Assessment 
Full-mouth  periodontal evaluation and radiographic examination were performed for 
all children (CF and control (C) group) to define their periodontal status. Clinical periodontal 
parameters included probing pocket depth (PPD), gingival index (GI)16, plaque index (PI)17 and 
bleeding on probing (BOP)17. All measurements were recorded at four sites (mesial, distal, 
buccal, lingual/palatinal) on each fully erupted tooth19,20 present by a single calibrated examiner 
(ZPKY) using a Williams periodontal probe.* Although the clinical attachment level was 
assessed, data was not presented due to absence of any attachment loss. Calculus formation was 
also determined by visually assessing the surface of each tooth and noted as present or absent21. 
Children in the periodontally healthy (H) group showed clinically healthy gingiva (GI=0), good 
oral hygiene, and PPD ≤3 mm with no clinical attachment and radiographic bone loss. Children 
with GI scores ≥1 and PPD ≤3 mm were defined as gingivitis (G). After completion of the 
periodontal examination, children were further classified into subgroups: CF and periodontally 
healthy (CF-H, N=6); CF with gingivitis (CF-G, N=4); systemically healthy and periodontally 
healthy (C-H, N=5); systemically healthy with gingivitis (C-G, N=5). 
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 All saliva samples (n=20) were collected in the morning hours (8.00-10.00 am) 
following overnight fasting one day after the clinical periodontal recordings. Children and 
their parents were requested not to drink or eat and to omit any oral hygiene procedures 
including brushing, flossing or mouth rinsing up to two hours prior to sampling. To obtain 
saliva samples, each participant expectorated for five minutes into sterile 50 mL 
polypropylene tubes after rinsing their mouth with tap water. Then, samples were centrifuged 
at 10,000 x g for 15 minutes at 4 °C. The supernatants (SNs) were immediately frozen and 
stored at -80 °C until further analysis. 
2.4. Analysis of TREM-1, PGLYRP1, Calprotectin, IL-1β and Total Protein Levels in 
Saliva 
Salivary TREM-1, PGLYRP1, Calprotectin and IL-1β levels were analysed by 
commercial enzyme-linked immunosorbent assay (ELISA) kits
†,‡,§,ǁǁ
 according to the 
manufacturer’s instructions and as described before
22
. The TREM-1 ELISA kit is detecting 
both soluble and membrane-bound TREM-1. Briefly, standards and diluted saliva SNs 
(TREM-1 (1:3), PGLYRP1 (1:60), Calprotectin (1:2000) and IL-1β (1:20)) were applied to 
pre-coated (capturing antibodies) 96 well plates (Nunc-Immuno™ MicroWell™ 96 well solid 
plates, Sigma) and incubated for two hours at room temperature (RT) after washing and 
blocking the plates. Biotin-conjugated detection antibodies were applied (1h at RT) followed 
by a 20 minutes incubation with horseradish peroxidase (HRP)-conjugated streptavidin at RT. 
Tetramethylbenzidine (TMB)-substrate solution was used to develop the assay and the 
reaction was stopped by applying 2N H2SO4. Absorbance was measured at 450 nm 
(wavelength correction = 540 nm). Finally, to determine the concentrations of TREM-1, 
PGLYRP1, Calprotectin and IL-1β, a four-parametric logistic standard curve was applied. 
Total protein levels were measured using the Pierce
TM
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2.5. Statistical Analysis 
The distribution of all variables were examined by Shapiro-Wilk normality test. 
Normality was provided by logarithmic transformation for data that was not normally 
distributed. Then, 2x2 factorial ANOVA was performed for comparisons of all descriptive 
variables between groups including the effect of systemic condition and periodontal status 
and interactions between CF and the periodontal status. As a categorical parameter, sex ratio 
was evaluated with chi-square test. Correlations between biochemical parameters and clinical 
periodontal parameters were determined by Pearson and Spearman’s rank correlation tests. 
All analyses were carried out using a statistical software program
# 
at α = 0.05 significance 
level. Receiver operating characteristic curves (ROC) were constructed to assess the ability of 
calprotectin as diagnostic aid. Statistical power calculations were performed for TREM-1 
using one-way ANOVA revealing a minimum sample size of 3 for each group to detect 
differences among the four groups at 3.5 f-type effect size level, with a power of 99% at 0.01 





3.1. Demographics and Clinical Findings 
Demographic characteristics of CF and systemically healthy (C) children and related 
subgroups are presented in Table 1. Age and sex showed no differences between CF and C 
groups as the groups were matched (P>0.05). In the subgroups, CF-G and C-G had a higher 
average age than CF-H and C-H children (P=0.033). RDW, neutrophil, lymphocyte and 
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normal (non pathological) for CF children, potentially influenced by common components of 
the disease, such as anemia, chronic infections and malabsorption. 
Table 2 shows the clinical periodontal findings of the CF and C groups. PPD, GI and 
PI were similar in CF and C children (P>0.05) while BOP scores were higher in the CF 
compared to the C group (P=0.001). Clinical findings for the subgroups are also presented in 
Table 2. All clinical periodontal parameters were higher in the gingivitis subgroups (CF-G 
and C-G) compared to the periodontally healthy subgroups (CF-H and C-H) (GI, PI, BOP: 
P<0.001; PPD: P=0.005). No calculus was detected in both groups.  
3.2. Biochemical Findings 
Salivary levels of TREM-1, PGLYRP1, IL-1β, calprotectin and total protein  were 
analysed (Table 3). Of the samples, 75% could detect TREM-1, 100% PGLYRP1, 90% IL-
1β, 95% calprotectin and 100% total protein with the rest showing values below the detection 
limit (23.1 pg/mL, 12.5 pg/ mL, 1.8 pg/mL, 36.1 pg/mL and 6.5 µg/mL, respectively). Mean 
concentrations (± SD, µg/mL) of calprotectin were 15.66±15.30 in CF children and 
3.99±4.58 in C children. Higher (by 3.9-fold) calprotectin levels were observed in the CF 
compared to the C group (P=0.017). No significant differences were observed in salivary 
levels of TREM-1, PGLYRP1, IL-1β and total protein between the CF and C group (all 
P>0.05). 
 The findings of the subgroups are demonstrated in Table 3. Mean salivary 
concentrations (± SD, pg/mL) of TREM-1 were 49.10±47.64 in the CF-H group, 
169.44±123.26 in the CF-G group, 38.04±42.13 in the C-H group and 242.17±141.21 in the 
C-G group (3.4-fold higher in CF-G compared to CF-H and 6.3-fold higher in C-G compared 
to C-H). Mean IL-1β concentrations (± SD, pg/mL) in the CF-H, CF-G, C-H and C-G groups 
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higher in CF-G compared to CF-H and 6.1-fold higher in C-G compared to C-H). Salivary 
concentrations of TREM-1 and IL-1β were elevated in the CF-G and C-G subgroups 
compared to the periodontally healthy (CF-H and C-H) subgroups (P=0.003). No significant 
difference was found in salivary PGLYRP1 and total protein levels among any of the 
subgroups (P>0.05). CF groups had higher salivary calprotectin levels compared to C groups 
(P=0.017). However no significant difference in calprotectin levels was observed between the 
gingivitis subgroups (CF-G and C-G) and the periodontally healthy (CF-H and C-H) 
subgroups (P>0.05). 
The ROC analysis (continuous analysis without threshold) for calprotectin showed an 
area under the curve (AUC) of 0.79 (95% CI 0.58-0.99, P=0.034) for the CF group compared 
to the C group. 
3.3. Correlation Analysis  
Table 4 presents the correlations of clinical periodontal parameters with biochemical findings 
in CF and C children. In the CF group, concentrations of salivary TREM-1 positively 
correlated with GI (P=0.009) and BOP (P=0.009), PGLYRP1 positively correlated with GI 
(P=0.038), BOP (P=0.038), IL-1β (P=0.011) and calprotectin (P=0.019), and IL-1β positively 
correlated with PI (P=0.022), BOP (P=0.048), PGLYRP1 (P=0.011) and calprotectin 
(P=0.013). Calprotectin positively correlated with PGLYRP1 (P=0.019) and IL-1β (P=0.013), 
but did not show an association with any of the clinical periodontal parameters (P>0.05). In 
the C group, levels of TREM-1 positively correlated with GI (P=0.003), PI (P=0.001), BOP 
(P=0.001), PGLYRP1 (P=0.043) and IL-1β (P=0.003), PGLYRP1 positively correlated with 
GI (P=0.048), PI (P=0.029), TREM-1 (P=0.043), IL-1β (P=0.004) and age (P=0.020), and 
IL-1β positively correlated with GI (P=0.008), PI (P=0.014), BOP (P=0.001), TREM-1 
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total protein levels (P=0.036) but, did not correlate with any clinical periodontal or 
biochemical parameter (P>0.05). 
 Correlations of medical, biochemical and clinical periodontal parameters of CF 
patients are presented in the supplement (see Supplementary Table 1 in online Journal of 
Periodontology). The primary interest was to investigate whether any of these medical or 
clinical periodontal parameters correlate with any of the four tested molecules (TREM-1, 
PGLYRP1, IL-1β, calprotectin). And indeed, salivary calprotectin levels were positively 
correlated with PCT (P=0.014), MPV (P=0.030) and thrombocyte levels (P=0.001). Salivary 
PGLYRP1 levels were positively correlated with thrombocyte levels (P=0.033). Furthermore, 
basophil levels positively correlated with GI (P=0.027) and BOP (P=0.036). All other 
correlations did not reach to significance (P>0.05). 
4. Discussion 
To the best of our knowledge the present study investigated, for the first time, the 
possible link between CF and periodontal disease based on periodontal parameters and 
biomarkers in saliva to unravel potential inflammatory response patterns. Interestingly, BOP 
scores were significantly elevated in CF patients compared to systemically healthy controls. 
This indicates that the systemic inflammation in CF patients can aggravate gingival 
inflammation and worsen the oral manifestation of periodontal disease. However, other 
periodontal parameters (PI and PPD) measured in this study did not show significant 
differences between CF patients and systemically healthy controls. It is known that in CF a 
mutation in the gene encoding the CFTR protein can negatively affect the salivary glands and 
the protective role of saliva that thus may result in a hyperinflammatory response with 
reduced host defence
5,23




This article is protected by copyright. All rights reserved. 
 
13 





between children with CF and systemically healthy controls.  
 We further investigated whether biochemical changes in saliva could support a possible 
link between CF and gingival inflammation in periodontal disease. Previous studies reported 
that salivary protein profiles differed between CF patients and healthy individuals24,25. Since 
salivary biomarkers are known to be important for diagnosis and prognosis of various 
autoimmune and inflammatory disorders including periodontal disease24, the study of such 
salivary markers might highlight a possible association between CF and gingival inflammation. 
In line with earlier reports, the present findings also showed that calprotectin as a marker for 
CF and present in sputum or serum of CF patients was significantly elevated in CF children 
compared to systemically healthy controls13,14. More interestingly, salivary calprotectin levels 
were positively correlated with procalcitonin levels, thrombocyte counts and mean platelet 
volume in CF patients. There is evidence that CF patients have elevated circulating platelet 
levels and platelet activation26, which is suggested to be an effect of the CFTR gene mutation. In 
CF patients, procalcitonin has also been evaluated as a marker of inflammation27, therefore the 
observed correlation between calprotectin and procalcitonin in the present study could reflect 
the ongoing systemic inflammatory responses in CF children. Furthermore, the ROC analysis 
identified a high discriminating capacity of calprotectin to differentiate between CF and 
systemically healthy children, supporting salivary calprotectin as a potential marker for 
the diagnosis of CF in children. Age dependency has been described for faecal calprotectin levels 
in CF and systemically healthy children below the age of four years28. However, since only one 
child within our study group was below the age of four (CF-H, 3 years of age) and the children in 
the C group were age and gender matched to the CF children, the age-dependent calprotectin 
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When subdividing the groups based on their periodontal status, calprotectin levels remained 
higher in CF patients compared to systemically healthy controls (with or without gingivitis) but 
the differences were no longer significant. A reason for this might be the rather small sample 
size after subdivision into the four subgroups (4-6 individuals). Different studies have already 
investigated calprotectin in periodontal disease and identified higher salivary calprotectin 
levels in experimental gingivitis29 and higher calprotectin levels in gingival crevicular fluid 
(GCF) of both periodontitis and gingivitis patients compared to healthy controls30. However, a 
recent study showed no significant differences in calprotectin levels in neither serum nor saliva 
in gingivitis patients compared to healthy controls, even though higher serum calprotectin 
levels were observed in aggressive periodontitis31. In this study, neither in CF children nor in 
the healthy controls, calprotectin was associated with any of the clinical periodontal parameters 
(PPD, PI, GI, BOP) indicating that salivary calprotectin may not be influenced by the periodontal 
status in these children. However, even though this study indicated for the first time that 
salivary calprotectin could be a potential marker to distinguish CF children with or without 
gingivitis from systemically healthy children, further studies are required to investigate the role 
of calprotectin in gingivitis or periodontal disease in general.  
Apart from calprotectin, TREM-1, its ligand PGLYRP1 and IL-1β, a downstream 
molecule of the TREM-1 signalling pathway, were investigated in saliva. We observed a 
positive correlation among TREM-1, PGLYRP1 and IL-1β in healthy control children but 
none of these molecules associated with calprotectin. The former association is supported by 
previous findings
7,8,22
 and could be attributed to the involvement of all three molecules in the 
TREM-1 signalling pathway. TREM-1, PGLYRP1 and IL-1β are also known to be regulated 
during gingival inflammation
22
. This fact together with our findings that the periodontal 
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did not correlate with TREM-1, PGLYRP1 and IL-1β in systemic health. In CF children 
however, PGLYRP1, IL-1β and calprotectin positively correlated with each other. An earlier 
study in patients with CF also proofed a positive association between TREM-1 and 
PGLYRP1 in plasma
10
. So it is not too surprising that calprotectin and PGLYRP1, an 
antimicrobial molecule also expressed by neutrophils and secreted upon neutrophil 
degranulation
11
, and IL-1β, a proinflammatory cytokine, positively correlate with each other 
during inflammation and/or infection. The fact, that TREM-1 monocyte-expression might be 
down-regulated in CF could explain why calprotectin and TREM-1 did not correlate. 
Although, salivary TREM-1, PGLYRP1 and L-1β levels were not able to distinguish 
between CF patients and systemically healthy controls, TREM-1 and IL-1β levels were 
significantly higher in the gingivitis subgroups compared to individuals with healthy 
periodontium, independently of CF. Therefore, salivary TREM-1 levels might closely reflect 
the presence of gingival inflammation in children. Up till now there is no study analysing 
TREM-1 levels in children with gingivitis or CF with periodontal health to compare our 
findings to. However, previous studies in adults or elderly are conform with our findings. 
Elevated TREM-1 levels in GCF in gingivitis
32
 and in saliva, GCF and serum in 
periodontitis
8,33 
have been reported compared to periodontal health in systemically healthy 
individuals. Recently, it also has been demonstrated in a human model of induced gingival 
inflammation that TREM-1 and PGLYRP1 in saliva are positively regulated in response to 
biofilm accumulation and removal
22
. So, it is also not surprising that TREM-1, PGLYRP1 
and IL-1β positively correlated with periodontal parameters, both in CF and healthy control 
children. Hence, it was highlighted for the first time that these molecules may have a crucial 
role in the early stage of periodontal disease and salivary TREM-1 may be substantial to 
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PGLYRP1 and IL-1β might directly reflect gingival inflammation while their features to 
reflect systemic inflammation in CF in children might rather be indirectly. The results of the 
current study need to be verified in larger studies of CF patients, however, it should be 
considered that CF is an autosomal recessive disease which is very rare
34
. 
5. Conclusion  
Children with CF had higher gingival inflammation scores and an altered salivary biomarker 
profile, especially in calprotectin levels, that is correlated with systemic inflammatory 
markers. In children with CF, pediatricians could check for signs of gingivitis by a simple 
oral examination and, if gingival inflammation is present, refer them to a dentist for dental 
care consultation. While these preliminary findings demonstrate that salivary calprotectin 
might have a chairside diagnostic potential for CF in children, further investigations in larger 
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Table 1. The Study Population Characteristics  
  
Cystic Fibrosis (CF) 
(N=10) 
 







































































































































































Age (yr.) 6.00±3.16 
 
8.50±2.88 5.60±1.51 8.60±2.51  




CRP: C-reactive protein; MCV: mean cell volume; MCH: mean corpuscular haemoglobin; MCHC: mean 
corpuscular haemoglobin concentration; RDW: red cell distribution width leukocyte; PCT: procalcitonin; MPV: 
mean platelet volume; CF-H: Cystic Fibrosis- Periodontally Healthy; CF-G: Cystic Fibrosis- Gingivitis; C-H: 
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parameters in children. *Values outside the reference range but not considered as a pathological finding; Values 
in bold: Significant differences (P<0.05) compared to CF-H and C-H; ND: not determined; NA: not applicable.  
 
 
Table 2. Clinical Periodontal Evaluation of Groups and Related Subgroups 
  








































































































This article is protected by copyright. All rights reserved. 
 
25 
















GI: gingival index; PI: plaque index; BOP: bleeding on probing; PPD: probing pocket depth; CF-H: Cystic 
Fibrosis- Periodontally Healthy; CF-G: Cystic Fibrosis- Gingivitis; C-H: Control- Periodontally Healthy; C-G: 
Control- Gingivitis. Values in bold for two main groups: Significant difference (P<0.05) from C group. 
Values in bold for subgroups: Significant differences (P<0.05) compared to CF-H and C-H. 
 
 



































173.18±218.85 162.83±194.71 0.609  
Calprotectin 
(µg/mL)  








Total Protein  
(µg/mL) 
 

































































CF-H: Cystic Fibrosis- Periodontally Healthy; CF-G: Cystic Fibrosis- Gingivitis; C-H: Control- Periodontally 
Healthy; C-G: Control- Gingivitis. Values in bold for two main groups: Significant difference (P<0.05) from 










Table 4. Correlations Between Clinical Periodontal and Biochemical Parameters in CF 
patients and Controls 





































 0.515 0.624 0.29
7 
-0.152 











0.515  0.758* 0.7
21* 
0.345 























r -0.080 0.225 0.455 0.304 0.455 0.297 0.72
1* 
0.745*  0.600 








-0.200 -0.152 0.345 0.164 0.60
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0.620 0.648*  0.815† 0.46
7 
0.515 

























r 0.306 0.417 -
0.033 
0.317 0.176 0.317 0.467 0.510  0.700* 
p 0.423 0.265  
0.932 






r 0.309 0.588 0.018 -
0.067 
0.061 0.164 0.515 0.468 0.7
00* 
 
p 0.385 0.074 0.960  
0.855 
0.868 0.651 0.128 0.172 0.03
6 
 
GI: gingival index; PI: plaque index; BOP: bleeding on probing; PPD: probing pocket depth; *Correlation 
(in bold) is significant at the 0.05 level (2-tailed); †Correlation (in bold) is significant at the 0.01 level (2-
tailed).  
 
